Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

11/12/24 10:34:15 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SANA alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 SANA BIOTECHNOLOGY INC COMMON STOCK Cusip #799566104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #799566104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 31,607,326 Item 6: 0 Item 7: 31,609,175 Item 8: 0 Item 9: 31,609,175 Item 11: 14.208% Item 12: HC Cusip #799566104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 31,609,175 Item 8: 0 Item 9: 31,609,175 Item 11: 14.208% Item 12: IN Item 1(a). Name of Issuer: SANA BIOTECHNOLOGY INC Item 1(b). Address of Issuer's Principal Executive Offices: 188 EAST BLAINE STREET, SUITE 400 SEATTLE, WA 98102 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 799566104 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 31,609,175 (b) Percent of Class: 14.208% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 31,609,175 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SANA BIOTECHNOLOGY INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of SANA BIOTECHNOLOGY INC, amounted to 12,246,419 shares or 5.504% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK IMPRESA MANAGEMENT LLC IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of SANA BIOTECHNOLOGY INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $SANA alert in real time by email

Recent Analyst Ratings for

$SANA

Date	Price Target	Rating	Analyst
11/5/2024		Mkt Outperform → Mkt Perform	JMP Securities
6/26/2024	$16.00	Buy	Rodman & Renshaw
1/16/2024	$12.00	Neutral → Buy	H.C. Wainwright
9/25/2023	$9.00	Mkt Outperform	JMP Securities
9/5/2023	$8.00	Buy	Citigroup
8/14/2023		Market Perform	TD Cowen
5/2/2023		Neutral	H.C. Wainwright
8/6/2021	$39.00 → $34.00	Neutral	Goldman Sachs

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

Chat with this insight

Recent Analyst Ratings for $SANA

$SANA Leadership Updates

Live Leadership Updates

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

$SANA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sana Biotechnology downgraded by JMP Securities

Rodman & Renshaw initiated coverage on Sana Biotechnology with a new price target

Sana Biotechnology upgraded by H.C. Wainwright with a new price target

$SANA Press Releases

Fastest customizable press release news feed in the world

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

$SANA SEC Filings

SEC Form 10-Q filed by Sana Biotechnology Inc.

Sana Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Sana Biotechnology Inc. filed SEC Form 8-K: Leadership Update

$SANA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Wyrick Susan D. claimed ownership of 147,512 shares (SEC Form 3)

Director Bishop Hans Edgar was granted 5,938 shares, increasing direct ownership by 0.10% to 5,790,489 units (SEC Form 4)

Director Mulligan Richard sold $1,195,740 worth of shares (300,000 units at $3.99), decreasing direct ownership by 10% to 2,698,121 units (SEC Form 4)

$SANA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

$SANA Large Ownership Changes

This live feed shows all institutional transactions in real time.